Anna Viitasalo1, Jussi Pihlajamäki2,3, Jussi Paananen1,4, Mustafa Atalay1, Virpi Lindi1, Timo A Lakka1,5,6. 1. Department of Physiology, Institute of Biomedicine, University of Eastern Finland, Kuopio Campus, Kuopio, Finland. 2. Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland. 3. Department of Clinical Nutrition and Obesity Center, Kuopio University Hospital, Kuopio, Finland. 4. Institute of Biomedicine, Bioinformatics Center, University of Eastern Finland, Kuopio, Finland. 5. Kuopio Research Institute of Exercise Medicine, Kuopio, Finland. 6. Department of Clinical Physiology and Nuclear Medicine, Kuopio University Hospital, Kuopio, Finland.
Abstract
BACKGROUND: The 167K allele in the TM6SF2 gene has been suggested to protect against cardiovascular disease at the cost of developing nonalcoholic fatty liver disease in adults. METHODS: We performed a cross-sectional study in a population sample of 462 Caucasian children aged 6-9 y, genotyped the polymorphism using HumanCoreExome BeadChip, and assessed several cardiometabolic risk factors. RESULTS: The 51 (11%) carriers of the 167K allele had higher plasma alanine aminotransferase (ALT) (20.8 vs. 18.4 U/l, P = 0.011) but lower plasma triglycerides (0.54 vs. 0.61 mmol/l, P = 0.024), total cholesterol (4.08 vs. 4.30 mmol/l, P = 0.016), and low-density lipoprotein (LDL) cholesterol (2.22 vs. 2.38 mmol/l, P = 0.012) than the 411 noncarriers. In factor analysis, the first factor was heavily loaded by plasma ALT (factor loading 0.63), triglycerides (-0.82), LDL cholesterol (-0.71), and waist circumference (0.61) in the carriers but not in the noncarriers. CONCLUSIONS: The carriers of the 167K allele have higher plasma ALT but lower plasma triglycerides and total and LDL cholesterol than the noncarriers already in childhood.
BACKGROUND: The 167K allele in the TM6SF2 gene has been suggested to protect against cardiovascular disease at the cost of developing nonalcoholic fatty liver disease in adults. METHODS: We performed a cross-sectional study in a population sample of 462 Caucasian children aged 6-9 y, genotyped the polymorphism using HumanCoreExome BeadChip, and assessed several cardiometabolic risk factors. RESULTS: The 51 (11%) carriers of the 167K allele had higher plasma alanine aminotransferase (ALT) (20.8 vs. 18.4 U/l, P = 0.011) but lower plasma triglycerides (0.54 vs. 0.61 mmol/l, P = 0.024), total cholesterol (4.08 vs. 4.30 mmol/l, P = 0.016), and low-density lipoprotein (LDL) cholesterol (2.22 vs. 2.38 mmol/l, P = 0.012) than the 411 noncarriers. In factor analysis, the first factor was heavily loaded by plasma ALT (factor loading 0.63), triglycerides (-0.82), LDL cholesterol (-0.71), and waist circumference (0.61) in the carriers but not in the noncarriers. CONCLUSIONS: The carriers of the 167K allele have higher plasma ALT but lower plasma triglycerides and total and LDL cholesterol than the noncarriers already in childhood.
Authors: Hovsep Mahdessian; Apostolos Taxiarchis; Sergej Popov; Angela Silveira; Anders Franco-Cereceda; Anders Hamsten; Per Eriksson; Ferdinand van't Hooft Journal: Proc Natl Acad Sci U S A Date: 2014-06-04 Impact factor: 11.205
Authors: Antti Saari; Ulla Sankilampi; Marja-Leena Hannila; Vesa Kiviniemi; Kari Kesseli; Leo Dunkel Journal: Ann Med Date: 2010-09-21 Impact factor: 4.709
Authors: Silvia Sookoian; Gustavo O Castaño; Romina Scian; Pablo Mallardi; Tomas Fernández Gianotti; Adriana L Burgueño; Julio San Martino; Carlos J Pirola Journal: Hepatology Date: 2015-01-05 Impact factor: 17.425
Authors: Oddgeir L Holmen; He Zhang; Yanbo Fan; Daniel H Hovelson; Ellen M Schmidt; Wei Zhou; Yanhong Guo; Ji Zhang; Arnulf Langhammer; Maja-Lisa Løchen; Santhi K Ganesh; Lars Vatten; Frank Skorpen; Håvard Dalen; Jifeng Zhang; Subramaniam Pennathur; Jin Chen; Carl Platou; Ellisiv B Mathiesen; Tom Wilsgaard; Inger Njølstad; Michael Boehnke; Y Eugene Chen; Gonçalo R Abecasis; Kristian Hveem; Cristen J Willer Journal: Nat Genet Date: 2014-03-16 Impact factor: 38.330
Authors: Anna Viitasalo; Aino-Maija Eloranta; Mustafa Atalay; Stefano Romeo; Jussi Pihlajamäki; Timo A Lakka Journal: Pediatr Res Date: 2016-07-13 Impact factor: 3.756